Drug, device makers made $6.5 billion in payments to healthcare providers in 2014, report shows
More than 1,110 teaching hospitals and 600,000 physicians received payments.
MD Anderson Cancer Center in Houston received an $11.8 million in services from from E.R. Squibb and a $10 million payment by drugmaker AstraZeneca.
Several teaching hospitals raked in millions in payments from device and drug manufacturers in 2014, according to new data from the Centers for Medicare and Medicaid Services released Tuesday that showed drug and medical device makers made close to $6.5 billion in payments to healthcare providers in 2014.
More than 1,110 teaching hospitals and 600,000 physicians received payments.
[Search the full table of payments to teaching hospitals]
Several major cancer hospitals ranked highest. For example, the Boston-based Dana Farber Cancer Institute received a payment worth $16.9 million in 2014 from E.R. Squibb and Sons, a subsidiary of pharmaceutical giant Bristol-Myers Squibb.
Meanwhile, MD Anderson Cancer Center in Houston received an $11.8 million in services from from E.R. Squibb and a $10 million payment by drugmaker AstraZeneca.
In total, MD Anderson received $93 million in payments in 2014 whil Dana Farber scored $40.1 million.
CMS released the data in its 2014 Open Payments database, which includes info on 11.4 million financial transactions.
Follow Healthcare Finance on Twitter and LinkedIn.
The release is mandatory under the Affordable Care Act, which required drug and device manufacturers to disclose payments to healthcare providers. About 30 percent of registered providers voluntarily reviewed the information, though CMS said it hoped to increase that number.
According to the data, physicians who registered with Open Payments received a median payment of $3,644, compared to $747 to non-registered providers.
In addition to drug and device manufacturers, group purchasing organizations must also disclose payment info.
Stay tuned for further analysis of this data.
Twitter: @HenryPowderly
